Cargando…
Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson–Gilford progeria syndrome fibroblasts
Hutchinson–Gilford progeria syndrome (HGPS) is a rare and fatal premature ageing disease in children. HGPS is one of several progeroid syndromes caused by mutations in the LMNA gene encoding the nuclear structural proteins lamins A and C. In classic HGPS the mutation G608G leads to the formation of...
Autores principales: | Bikkul, Mehmet U., Clements, Craig S., Godwin, Lauren S., Goldberg, Martin W., Kill, Ian R., Bridger, Joanna M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223735/ https://www.ncbi.nlm.nih.gov/pubmed/29907918 http://dx.doi.org/10.1007/s10522-018-9758-4 |
Ejemplares similares
-
Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells
por: Mehta, Ishita S, et al.
Publicado: (2011) -
Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts
por: Gabriel, Diana, et al.
Publicado: (2017) -
Defective Lamin A-Rb Signaling in Hutchinson-Gilford Progeria Syndrome and Reversal by Farnesyltransferase Inhibition
por: Marji, Jackleen, et al.
Publicado: (2010) -
All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype
por: Pellegrini, Camilla, et al.
Publicado: (2015) -
Hutchinson-Gilford progeria syndrome
por: Bhukya, Amar Singh, et al.
Publicado: (2015)